Episode Details
Back to Episodes
Apr 05, 2026 | Lilly Foundayo vs Novo Oral Wegovy Launch War; Trump Signs 100% Pharma Tariff
Description
Trump's 100% tariff on patented drugs reshapes pharmastrategy—tiered exemptions create winners and losers. Lilly's Foundayo approved; Novo fires back with ORION data showing oral Wegovy's tolerability edge. Plus Biogen-Apellis, Q1's $47B M&A wave, and the first R&Dpipeline contraction in 30 years.
visit us at www.thepharmacloseout.com
pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, pharma tariff, Trump pharmaceutical tariff, Section 232, Foundayo, orforglipron, Eli Lilly, oral GLP-1, Novo Nordisk, oral Wegovy, semaglutide, ORION study, obesity drugs, Biogen, Apellis, CVR, contingent value rights, biopharma M&A, Orca-T, Orca Bio, Blackstone life sciences, R&D pipeline, Citeline, sparsentan, Travere,AXS-05, Axsome, AACR, AAN, Lilly, Merck